We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Minimally Invasive Way to Remove Pituitary Tumors

By HospiMedica staff writers
Posted on 13 Feb 2003
Removing pituitary tumors through the nasal cavity rather than beneath the upper lip offers patients a minimally invasive alternative with similar results, less discomfort, and faster recovery, according to a new study published in the February 2003 issue of the Journal of Neurosurgery.

The older, sublabial approach involves an incision beneath the upper lip and extensive dissection in and around the nasal cavity. More...
The procedure can cause long-term patient discomfort, including impaired nasal function and numbness of the upper lip and teeth.

In the new study, 100 consecutive patients who underwent the new endonasal procedure at the University of California, Los Angeles, Medical Center (UCLA, USA) later completed a questionnaire prepared by the researchers. Fourteen of these respondents had undergone prior sublabial procedures. Among the findings from the questionnaire were that remission rates with the new procedure were comparable to those found with the sublabial procedure. Twelve of the 14 patients with prior sublabial surgery preferred the new procedure.

The most common post-surgical complaints were nasal packing, removing of packing, and mouth breathing. Around three months after surgery, 83% of patients had no facial pain, 75% had no nasal congestion, 77% had no decreased nasal airflow, 73% had no decreased sense of smell, and 87% had no upper lip numbness.

"Our study suggests the direct endonasal approach to removing pituitary tumors offers a more direct surgical route, a low complication rate, and minimal postoperative discomfort,” said Dr. Daniel Kelly, associate professor of neurosurgery at the UCLA School of Medicine.




Related Links:
UCLA Medical Ctr

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.